Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Clinical trial NCT05873205 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05873205
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-21
- Primary completion
- 2027-06-29
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.